- CIMICIFUGOSIDE
-
- $1.00
-
2019-12-24
- CAS:66176-93-0
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| | CIMICIFUGOSIDE Basic information |
| Product Name: | CIMICIFUGOSIDE | | Synonyms: | CIMICIFUGOSIDE;CIMICIFUGOSIDE USP/EP/BP;Prim-O-glucosylcimifygin;β-D-Xylopyranoside, (3β,12β,16β,23R,24R,25S)-12-(acetyloxy)-16,23:23,26:24,25-triepoxy-26-hydroxy-9,19-cyclolanost-7-en-3-yl | | CAS: | 66176-93-0 | | MF: | C37H54O11 | | MW: | 674.82 | | EINECS: | | | Product Categories: | Miscellaneous Natural Products | | Mol File: | 66176-93-0.mol |  |
| | CIMICIFUGOSIDE Chemical Properties |
| density | 1.38±0.1 g/cm3(Predicted) | | pka | 12.14±0.70(Predicted) |
| | CIMICIFUGOSIDE Usage And Synthesis |
| Uses | Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity[1]. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function[2]. | | Biological Activity | Cimicifugoside, a triterpenoid extracted from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that synergistically enhances the cytotoxic effect of methotrexate. It has immunosuppressive activity that preferentially targets B cell function, requiring larger doses to inhibit T cell function. | | target | | | References | [1] Yawata A, et al. Inhibition of nucleoside transport and synergistic potentiation of methotrexate cytotoxicity by cimicifugoside, a triterpenoid from Cimicifuga simplex. Eur J Pharm Sci. 2009 Nov 5;38(4):355-61. DOI:10.1248/bpb1978.3.643
[2] Hemmi H, et al. The immune response of splenic lymphocytes after cimicifugoside treatment in vitro and pretreatment in vivo. J Pharmacobiodyn. 1980 Dec;3(12):643-8. DOI:10.1248/bpb1978.3.643 |
| | CIMICIFUGOSIDE Preparation Products And Raw materials |
|